This research explores targeted treatments for glomerular diseases, revealing implications for patient selection and treatment effectiveness.
The imminent availability of multiple therapeutic complement inhibitors, which target different complement pathway components, could revolutionise treatment for a broad range of kidney diseases. However, the complexity of complement activity within and between kidney diseases, for which IgA nephropathy is an illustrative example, and the possible adverse effects of complement inhibition mean robust patient selection and stratification to appropriately targeted inhibitors will be needed to maximise this therapeutic opportunity. Despite promising candidates, novel biomarkers that stratify patients to targeted complement inhibition have not yet been validated for clinical practice.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: